In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The Peptide Craze Ground Truths US FDA to convene expert panel to review wider access to some peptides Reuters FDA mulls compounding for peptides previously flagged over safety risks BioSpace BPC 157: Prohibited peptide and unapproved drug in supplements